[{"address1": "1200 Brickell Avenue", "address2": "Suite 1950 #1183", "city": "Miami", "state": "FL", "zip": "32183", "country": "United States", "phone": "786-432-9792", "website": "https://mirapharmaceuticals.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Erez  Aminov", "age": 44, "title": "CEO & Chairman", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 337047, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Yanez M.B.A.", "age": 50, "title": "CFO, Secretary & Treasurer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 338774, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Itzchak  Angel Ph.D.", "title": "Chief Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.7101, "open": 0.712, "dayLow": 0.72, "dayHigh": 0.735, "regularMarketPreviousClose": 0.7101, "regularMarketOpen": 0.712, "regularMarketDayLow": 0.72, "regularMarketDayHigh": 0.735, "forwardPE": -1.8299999, "volume": 10285, "regularMarketVolume": 10285, "averageVolume": 124585, "averageVolume10days": 38850, "averageDailyVolume10Day": 38850, "marketCap": 10819619, "fiftyTwoWeekLow": 0.631, "fiftyTwoWeekHigh": 6.95, "fiftyDayAverage": 0.80708, "twoHundredDayAverage": 1.826925, "currency": "USD", "enterpriseValue": 7292186, "floatShares": 9068369, "sharesOutstanding": 14780900, "sharesShort": 14664, "sharesShortPriorMonth": 42254, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.001, "heldPercentInsiders": 0.29108, "heldPercentInstitutions": 0.04265, "shortRatio": 0.32, "shortPercentOfFloat": 0.0016, "impliedSharesOutstanding": 14780900, "bookValue": 0.214, "priceToBook": 3.4205606, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -12359070, "trailingEps": -0.66, "forwardEps": -0.4, "52WeekChange": -0.8859813, "SandP52WeekChange": 0.2586832, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MIRA", "underlyingSymbol": "MIRA", "shortName": "MIRA Pharmaceuticals, Inc.", "longName": "MIRA Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1692019800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a71f8b50-3996-3ccd-98e2-c993481fee2f", "messageBoardId": "finmb_1793899557", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.732, "targetHighPrice": 16.5, "targetLowPrice": 16.5, "targetMeanPrice": 16.5, "targetMedianPrice": 16.5, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 3528695, "totalCashPerShare": 0.239, "totalDebt": 1273, "quickRatio": 5.412, "currentRatio": 5.696, "debtToEquity": 0.04, "returnOnAssets": -2.6611, "returnOnEquity": -18.077961, "freeCashflow": -4546209, "operatingCashflow": -4506633, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-21"}]